Novartis Articles
Sales Advance 8% In 1996 At Novartis
3 February 1997
New Xenotransplantation Guidelines Adopted In UK
3 February 1997
Alexion Grants Gene Therapy Technology Rights To Novartis
27 January 1997
Novartis USA Names President And CEO
27 January 1997
Appointment At Astra Merck
27 January 1997
US H2 Blocker Boom Forecast To Slow Down
27 January 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
EUROPEAN AND LONDON STOCK COMMENT
20 January 1997
Novartis To Buy Remaining Interest In SyStemix
20 January 1997
Many Firms In USA Recruiting Again
20 January 1997
Drug Firms Affected By "Slowdown" Of German Market
13 January 1997
US Biotech Financings Up 25% In 1996
13 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
AIG To Invest $5.1m In Novartis Unit
13 January 1997
EUROPEAN AND LONDON STOCK COMMENT
13 January 1997
SangStat's Ciclosporin "Bioequivalent" To Neoral
13 January 1997
Acquisitions And Mergers Continue, Led By Novartis
6 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
No Hidden Surprises From US FTC For Birth Of Novartis
6 January 1997
EUROPEAN STOCK COMMENT
23 December 1996
Novartis Gets Go-Ahead From US FTC
23 December 1996
New Over-The-Counter League From IMS
23 December 1996
Sandoz Sells MBT Division
9 December 1996
Stock Commentary: Europe
9 December 1996
Who Is Roche After ?
2 December 1996
"Indian Combinations"
25 November 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Is Drug Innovation The Key To Leading-Edge Growth?
28 October 1996
Sandoz, Knoll Buy Into Generics As Gehe Opts Out
21 October 1996
Sandoz To Sell Herbicide Unit To Progress Novartis Merger
14 October 1996
World OTC Market Growth Disappoints In 1995
14 October 1996
EUROPEAN STOCK COMMENT
7 October 1996
Fears Of Delay To Novartis Merger
30 September 1996
James Callahan Resigns From Ciba-Geigy
16 September 1996
Swiss Companies Disappoint In '96 First Half
9 September 1996
Novartis Makes Site Decisions
2 September 1996
SmithKline Beecham: A Leader In Spanish Market
19 August 1996
Senior Management Appointments At Novartis UK
5 August 1996
Europe Stock Comment
5 August 1996
EUROPE STOCK COMMENT
29 July 1996
Resignation At T Cell Sciences
22 July 1996
**Stop Press**EU Approves Formation Of Novartis
22 July 1996
EUROPE STOCK COMMENT
22 July 1996
Strong Growth From Ciba In 1996 First Half
22 July 1996
Changes To Be Made To EU Competition Rules?
15 July 1996
Europe stock comment
15 July 1996
Novartis Ruling To Come Soon?
8 July 1996
Europe Stock Comment
8 July 1996
Novartis Names Management
8 July 1996
EUROPE STOCK COMMENT
1 July 1996
Bayer Scouting For Merger Partner?
24 June 1996
Xenova Starts Trials Of Second Cancer Drug
17 June 1996
Israel's Promedico To Set-Up Own Production
3 June 1996
Novartis' Japanese Management
27 May 1996
Europe Stock Comment
20 May 1996
Encouraging US OTC Makers Into Nutraceuticals
20 May 1996
Novartis Appointments
13 May 1996
Europe Stock Comment
13 May 1996
Senior Managment Appointments At Novartis
13 May 1996
Industry Changes: View From The Equity Market
13 May 1996
Europe Stock Comment
6 May 1996
Novartis Gets Approval At Ciba And Sandoz AGMs
29 April 1996
Strong Swiss Franc Impacts On Ciba's 1st Quarter
29 April 1996
Spain's Esteve Sees Independent Future
15 April 1996
Transforming The Pharmaceutical Industry
15 April 1996
Novartis Will Be A Leading Player In OTC Market
8 April 1996
Europe Stock Comment
1 April 1996
Corporate Ranking - A New Order For 1995
1 April 1996
EUROPE STOCK COMMENT
25 March 1996
W-Lambert And Schering-Plough Merger Targets?
25 March 1996
Hoechst Heads Into An Uncertain Future
25 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Europe Stock Comment
18 March 1996
Independent Position To Be Maintained At Zeneca
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Mergermania In Euro Drug Industry: Will It Continue?
18 March 1996
Novartis Muscles In As Sandoz And Ciba Merge
11 March 1996
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
